Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7915387 | 0.88 | ADORA2A (0.60) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL5347463 | 0.87 | CYP1A2 (0.66) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL784431 | 0.85 | ADORA2A (0.54) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL217116 | 0.85 | CYP2C19 (0.60) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL5358560 | 0.84 | ADORA2A (0.53) | ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL6882745 | 0.84 | ADORA3 (0.62) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL1533270 | 0.84 | ADORA3 (0.62) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL8506519 | 0.84 | CYP1A2 (0.55) | ADORA3ADORA1 | |
| SCHEMBL2208478 | 0.82 | ADORA2A (0.60) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL27690308 | 0.82 | ADORA2A (0.60) | ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109414511-B | Antisense oligomers for treating diseases associated with acid alpha-glucosidase genes and methods of use thereof | 萨勒普塔医疗公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-104411831-B | Boronic acid conjugates of oligonucleotide analogs | 萨勒普塔医疗公司 | 2020-08-11 | — | — | CN | disclosed |
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20080248584-A1 | Biopolymer ionization; liquid chromatography | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2008-10-09 | — | — | US | disclosed |
| EP-1506959-A2 | Derivatised molecules for mass spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2005-02-16 | — | — | EP | disclosed |
| US-20030166896-A1 | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| US-6528639-B2 | Active ribozyme | RIBOZYME PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20010006801-A1 | BASE-MODIFIED ENZYMATIC NUCLEIC ACID | USMAN NASSIM (US) | 2001-07-05 | — | — | US | disclosed |
| US-5891684-A | RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5879938-A | RIBOZYME WITH INCREASED ACTIVITY BY SUBSTITUTION OF MODIFIED NUCLEOTIDE INTO SUBSTRATE BINDING ARM OR CATALYTIC CORE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5767263-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| US-5698685-A | Morpholino-subunit combinatorial library and method | ANTIVIRALS INC. (US) | 1997-12-16 | — | — | US | disclosed |
| US-5672501-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5672511-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5506337-A | Morpholino-subunit combinatorial library and method | ANTIVIRALS INC. (US) | 1996-04-09 | — | — | US | disclosed |
| WO-1995031459-A1 | MORPHOLINO-SUBUNIT COMBINATORIAL LIBRARY AND METHOD | ANTIVIRALS INC. (US) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080248584-A1 | Biopolymer ionization; liquid chromatography | F12, F13B, F13A1 | ADORA3 3279/4885ADORA1 3717/4885ADORA2A 3351/4885 |
| US-20030166896-A1 | Base-modified enzymatic nucleic acid | RNASE1, RNGTT, RNASEL | ADORA3 1864/4885ADORA1 2304/4885ADORA2A 1896/4885 |
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | F3, TBCA, GYPA | ADORA3 2846/4885ADORA1 3388/4885ADORA2A 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.